BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 22527108)

  • 1. Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy.
    Ottini L; Silvestri V; Rizzolo P; Falchetti M; Zanna I; Saieva C; Masala G; Bianchi S; Manoukian S; Barile M; Peterlongo P; Varesco L; Tommasi S; Russo A; Giannini G; Cortesi L; Viel A; Montagna M; Radice P; Palli D
    Breast Cancer Res Treat; 2012 Jul; 134(1):411-8. PubMed ID: 22527108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy.
    Ottini L; Rizzolo P; Zanna I; Falchetti M; Masala G; Ceccarelli K; Vezzosi V; Gulino A; Giannini G; Bianchi S; Sera F; Palli D
    Breast Cancer Res Treat; 2009 Aug; 116(3):577-86. PubMed ID: 18819001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
    Falchetti M; Lupi R; Rizzolo P; Ceccarelli K; Zanna I; Calò V; Tommasi S; Masala G; Paradiso A; Gulino A; Giannini G; Russo A; Palli D; Ottini L
    Breast Cancer Res Treat; 2008 Jul; 110(1):161-7. PubMed ID: 17661168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
    Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy.
    Palli D; Falchetti M; Masala G; Lupi R; Sera F; Saieva C; D'Amico C; Ceroti M; Rizzolo P; Caligo MA; Zanna I; Ottini L
    BMC Cancer; 2007 Sep; 7():170. PubMed ID: 17767707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas.
    Deb S; Jene N; ; Fox SB
    BMC Cancer; 2012 Nov; 12():510. PubMed ID: 23146383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients.
    Kwiatkowska E; Teresiak M; Filas V; Karczewska A; Breborowicz D; Mackiewicz A
    Clin Cancer Res; 2003 Oct; 9(12):4452-9. PubMed ID: 14555518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
    Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
    Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
    Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A
    Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A gene-environment interaction between occupation and BRCA1/BRCA2 mutations in male breast cancer?
    Palli D; Masala G; Mariani-Costantini R; Zanna I; Saieva C; Sera F; Decarli A; Ottini L
    Eur J Cancer; 2004 Nov; 40(16):2474-9. PubMed ID: 15519522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.
    Sánchez-Muñoz A; Román-Jobacho A; Pérez-Villa L; Sánchez-Rovira P; Miramón J; Pérez D; Sáez MI; de Luque V; Medina L; Ramírez-Tortosa CL; Vicioso L; Medina JA; Ribelles N; Alba E
    Oncology; 2012; 83(4):228-33. PubMed ID: 22907070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States.
    Tchou J; Ward MR; Volpe P; Palma MD; Medina CA; Sargen M; Sonnad SS; Godwin AK; Daly M; Winchester DJ; Garber J; Weber BL; Domchek S; Nathanson KL
    Clin Breast Cancer; 2007 Jun; 7(8):627-33. PubMed ID: 17592676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of bilateral breast cancers in BRCA carriers.
    Weitzel JN; Robson M; Pasini B; Manoukian S; Stoppa-Lyonnet D; Lynch HT; McLennan J; Foulkes WD; Wagner T; Tung N; Ghadirian P; Olopade O; Isaacs C; Kim-Sing C; Møller P; Neuhausen SL; Metcalfe K; Sun P; Narod SA
    Cancer Epidemiol Biomarkers Prev; 2005 Jun; 14(6):1534-8. PubMed ID: 15941968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers.
    Bertucci F; Finetti P; Cervera N; Charafe-Jauffret E; Mamessier E; Adélaïde J; Debono S; Houvenaeghel G; Maraninchi D; Viens P; Charpin C; Jacquemier J; Birnbaum D
    Cancer Res; 2006 May; 66(9):4636-44. PubMed ID: 16651414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: results from a multicenter study in Italy.
    Silvestri V; Rizzolo P; Scarnò M; Chillemi G; Navazio AS; Valentini V; Zelli V; Zanna I; Saieva C; Masala G; Bianchi S; Manoukian S; Barile M; Pensotti V; Peterlongo P; Varesco L; Tommasi S; Russo A; Giannini G; Cortesi L; Viel A; Montagna M; Radice P; Palli D; Ottini L
    Eur J Cancer; 2015 Nov; 51(16):2289-95. PubMed ID: 26248686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants.
    Delgado L; Fernández G; Grotiuz G; Cataldi S; González A; Lluveras N; Heguaburu M; Fresco R; Lens D; Sabini G; Muse IM
    Breast Cancer Res Treat; 2011 Jul; 128(1):211-8. PubMed ID: 21190077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.
    Vicus D; Finch A; Rosen B; Fan I; Bradley L; Cass I; Sun P; Karlan B; McLaughlin J; Narod SA;
    Gynecol Oncol; 2010 Aug; 118(2):155-9. PubMed ID: 20452659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of BRCA1 and BRCA2 mutations in male breast cancer patients in Canada.
    Wolpert N; Warner E; Seminsky MF; Futreal A; Narod SA
    Clin Breast Cancer; 2000 Apr; 1(1):57-63; discussion 64-5. PubMed ID: 11899391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
    Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
    Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.